13 completed, 3 active not recruiting, 2 terminated, 2 unknown. 7 Phase 3, 6 Phase 2, 2 Phase 1, 2 Phase 4.
Follow Generalized Pustular Psoriasis: new trials by email Literature Review of Generalized Pustular Psoriasis trials Research Report on Generalized Pustular Psoriasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Generalized Pustular Psoriasis Registry in Costa Rica Generalized Pustular Psoriasis, Generalized Pustular Psoriasis (GPP) | Not yet recruiting | Caja Costarricense de Seguro Social | 50 | 2026-05-01 | 2026-03-09 | |
| Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis Spevigo® - Generalized Pustular Psoriasis | Withdrawn | Boehringer Ingelheim | 2026-03-31 | 2026-03-31 | ||
| A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis TQH2929 Injections, TQH2929 Placebo - Generalized Pustular Psoriasis | Phase 2 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 36 | 2026-03-19 | 2026-08-03 |
| Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis HB0034 - Generalized Pustular Psoriasis | Phase 2 / Phase 3 | Unknown | Shanghai Huaota Biopharmaceutical Co., Ltd. | 33 | 2024-09-02 | 2025-02-14 |
| A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP) TQH2929 Injection - Generalized Pustular Psoriasis | Phase 1 | Active not recruiting | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 9 | 2024-06-19 | 2025-07-30 |
| A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis TAK-279 - Generalized Pustular Psoriasis, Erythrodermic Psoriasis | Phase 3 | Completed | Takeda | 18 | 2024-03-19 | 2026-11-04 |
| A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis JNJ-77242113 - Generalized Pustular Psoriasis, Erythrodermic Psoriasis | Phase 3 | Active not recruiting | Janssen Pharmaceutical K.K. | 19 | 2024-02-09 | 2026-09-28 |
| A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares Spesolimab - Generalized Pustular Psoriasis | Phase 4 | Completed | LEO Pharma | 42 | 2023-10-22 | 2026-10-26 |
| CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry Generalized Pustular Psoriasis | Completed | CorEvitas | 46 | 2023-09-19 | 2026-11-06 | |
| PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms Spesolimab - Generalized Pustular Psoriasis | Completed | Boehringer Ingelheim | 52 | 2023-04-18 | 2025-10-20 | |
| HB0034 in Patients With Generalized Pustular Psoriasis (GPP) HB0034 - Generalized Pustular Psoriasis | Phase 1 | Completed | Shanghai Huaota Biopharmaceutical Co., Ltd. | 9 | 2022-11-06 | 2024-01-23 |
| Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP Double-blind 200 mg imsidolimab, Placebo, Open-label 200 mg imsidolimab - Generalized Pustular Psoriasis | Phase 3 | Terminated | Vanda Pharmaceuticals | 42 | 2022-04-21 | 2026-03-27 |
| Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP 750 mg Imsidolimab, 300 mg Imsidolimab, Placebo - Generalized Pustular Psoriasis | Phase 3 | Completed | Vanda Pharmaceuticals | 45 | 2022-04-14 | 2026-03-17 |
| An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options spesolimab - Generalized Pustular Psoriasis | Phase 3 | Completed | Boehringer Ingelheim | 39 | 2022-03-15 | 2025-10-20 |
| An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options spesolimab - Generalized Pustular Psoriasis | Phase 3 | Completed | Boehringer Ingelheim | 11 | 2022-02-17 | 2025-02-25 |
| A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis Spesolimab, Placebo - Generalized Pustular Psoriasis | Phase 2 | Completed | Boehringer Ingelheim | 123 | 2020-06-04 | 2025-10-20 |
| A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis Ixekizumab - Generalized Pustular Psoriasis, Erythrodermic Psoriasis | Phase 4 | Completed | Eli Lilly and Company | 12 | 2019-07-05 | 2021-08-13 |
| Biologic Therapy for Generalized Pustular Psoriasis After exclusion of relevant contraindications, participants received subcutaneous ustekinumab/secukinumab therapy. - Generalized Pustular Psoriasis | Completed | Chao Ji | 65 | 2019-07-01 | 2024-04-30 | |
| Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study Spesolimab - Generalized Pustular Psoriasis | Phase 2 | Active not recruiting | LEO Pharma | 131 | 2019-05-29 | 2026-09-01 |
| Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis Spesolimab, Placebo - Generalized Pustular Psoriasis | Phase 2 | Completed | Boehringer Ingelheim | 53 | 2019-01-31 | 2025-10-16 |
Showing 20 of 22. Sign in to see all of them.
Psoriasis (22)
Skin Diseases (22) · Skin Diseases, Papulosquamous (22) · Skin and Connective Tissue Diseases (22)
spesolimab (8) · Double-Blind Method (1) · Genotype (1) · Incidence (1) · Prevalence (1) · Standard of Care (1) · ixekizumab (1)
Boehringer Ingelheim (6) · Vanda Pharmaceuticals (3) · LEO Pharma (2) · Shanghai Huaota Biopharmaceutical Co., Ltd. (2) · Caja Costarricense de Seguro Social (1) · Chao Ji (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (1) · CorEvitas (1) · Eli Lilly and Company (1) · Janssen Pharmaceutical K.K. (1) · Peking University Third Hospital (1) · Takeda (1)
China (10) · Japan (8) · South Korea (8) · United States (8) · France (6) · Germany (6) · Malaysia (6) · Taiwan (6) · Thailand (6) · Tunisia (6) · Spain (5) · Turkey (Türkiye) (4) · Australia (3) · Belgium (3) · Italy (3)
Jianzhong Zhang, PhD (1) · Siyan Zhan, PhD (1) · Zhang Furen, Doc. (1)
PMID 42047557, PMID 33785490, PMID 34936739, PMID 34967916, PMID 36333618, PMID 37840119, PMID 39104539, PMID 40057892
2017 (2), 2018 (2), 2023 (1)